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Introduction
Missense mutations in cancer cells can generate unique T cell epi-
topes.1 Natural antigen-specific T-cell responses against missense 
mutant epitopes in acute myeloid leukemia (AML), melanoma, 
renal and lung cancer have been discovered using traditional dis-
covery methods based on CD8+ tumor infiltrating lymphocytes 
(TILs).2–6 Such foreign epitopes have been shown is to facilitate 
immunosurveillance and cancer control in chemically-induced 
murine models of carcinogens.7 Furthermore, sequencing efforts 
have identified 50 mutated peptides that can serve as rejection 
antigens in transplanted B16 murine melanoma.8 The marked 
increase in tumor sequencing efforts has provided an opportu-
nity to discover mutant epitopes that strongly bind to human 
HLA, compared with wild-type peptides, and may thus be effec-
tive mediators of T-cell responses. Thus, knowledge of a patient’s 
HLA type and missense mutation profile provides the opportu-
nity to develop personalized peptide vaccines. Evidence support-
ing the efficacy of vaccination strategies based on mutant epitopes 
antigen-specific immune responses against peptides derived from missense gene mutations have been identified in 
multiple cancers. The application of personalized peptide vaccines based on the tumor mutation repertoire of each cancer 
patient is a near-term clinical reality. These peptides can be identified for pre-validation by leveraging the results of massive 
gene sequencing efforts in cancer. In this study, we utilized NetMhc 3.2 to predict nanomolar peptide binding affinity 
to 57 human hLa-a and B alleles. all peptides were derived from 5,685 missense mutations in 312 genes annotated as 
functionally relevant in the cancer Genome project. Of the 26,672,189 potential 8–11 mer peptide-hLa pairs evaluated, 0.4% 
(127,800) display binding affinities < 50 nM, predicting high affinity interactions. These peptides can be segregated into two 
groups based on the binding affinity to hLa proteins relative to germline-encoded sequences: peptides for which both the 
mutant and wild-type forms are high affinity binders, and peptides for which only the mutant form is a high affinity binder. 
current evidence directs the attention to mutations that increase hLa binding affinity, as compared with cognate wild-type 
peptide sequences, as these potentially are more relevant for vaccine development from a clinical perspective. Our analysis 
generated a database including all predicted hLa binding peptides and the corresponding change in binding affinity as a 
result of point mutations. Our study constitutes a broad foundation for the development of personalized peptide vaccines 
that hone-in on functionally relevant targets in multiple cancers in individuals with diverse hLa haplotypes.
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has already been generated. For instance, peptides derived from 
codon 3 mutations in RAS family members can readily induce 
immunity in patients with pancreatic, lung, and colon cancer 
patients.1,9–14
However, RAS mutations do not generate optimal antigens 
in most cancer patients. Indeed, RAS is a relatively commonly 
mutated gene, yet is present only in a minority of patients. Models 
of peptide-HLA binding affinity can facilitate the identification of 
novel and “personal” targets for cancer vaccines. To the best of our 
knowledge, computational methods to discover mutant epitopes 
and the differential binding affinity to HLA were first applied 
by Segal et al. to a data set from breast and colorectal tumors.15 
In this study, 1,152 peptides were interrogated for HLA-A*02:01 
binding in silico. Similarly, Warren et al. subjected a general sur-
vey of mutations to multiple in silico HLA-binding algorithms 
in an effort to identify a polyvalent peptide vaccine optimized 
for prophylactic use.16 HLA allelic frequency in the United States, 
mutation frequency and tumor subtype frequency were given 
equal consideration to generate the proposed vaccine formulation.1282  OncoImmunology  Volume 1 Issue 8
Figure 1. allelic distribution of tight binding mutated peptide-hLa pairs. allelic distribution of predicted tight binding (affinity score < 50 nM) 
mutated peptides from the cancer Gene census among Mhc class I alleles. (A) human hLa (n = 52), null data not shown for n = 5 hLa alleles (n = 5). 
(B) Murine h-2 alleles (n = 6). (C) Rhesus macaque Mamu alleles (n = 7). (D) chimpanzee patr alleles (n = 9).
HLA binding affinity upon mutation. In addition, we present 
a set of peptides predicted to bind HLA with similar affinity 
before and after a cancer-associated mutation. Thus, we offer a 
foundational database to support research of hypotheses related 
to the immunogenicity of peptides derived from missense cancer-
associated mutations.
Results
Execution of MHC Class I binding peptide prediction with 
NetMHC 3.2. In order to identify peptides that may serve as 
tumor rejection antigens based on the predicted ability to bind 
human HLA, a database of missense mutation-derived peptides 
was assembled from the Catalogue of Somatic Mutations in 
Cancer (COSMIC) database. Mutations (n = 5,590) from 312 
genes (Table S1) that are represented in the COSMIC database 
were used as a resource for the amino acid substitution affecting 
the wild-type sequence. Short peptide strings of 8, 9, 10 and 11 
Since the binding affinity of a peptide for HLA proteins 
is associated with the immunogenicity of the peptide, com-
putational prediction is a convenient and practical first step 
toward the identification of optimal vaccine targets for cancer 
therapy.17 The ongoing development of peptide-MHC binding 
algorithms has benefitted from progressively more empirical 
binding data, allowing for increased prediction accuracy.18,19 By 
means of the artificial neural network-based prediction algorithm 
NetMHC3.2, developed by Lundegaard et al., highly accurate 
predictions of peptide binding to large numbers of HLA alleles 
are now possible.18 The prediction of peptide sequence-dependent 
antigen presentation, which entails multiple steps including pro-
teosomal cleavage and TAP binding, is by far more complex (and 
hence less developed) than that of peptide-HLA interactions. 
Moreover, peptide processing is highly variable across multiple 
types of cancer cells and inflammatory states.
The analysis performed in this study yields a potential func-
tional class of immunotherapeutic targets that possess increased From the 26,672,189 mutated peptides and 57 distinct human 
HLA alleles interrogated, 127,801 (0.3%) unique peptide-HLA 
pairs achieved a binding score of 50 nM of less (i.e., tight bind-
ing). This set of peptides was subjected to further analysis.
Mutation-mediated alteration in HLA-binding affinity. For 
the purpose of comparison, a delta table was generated to display 
the change in predicted HLA affinity that occurred as a result of 
amino acid lengths were generated from every mutation in the 
primary database. Each mutation resulted in 76 unique strings. 
In total, 26,672,189 peptides were generated for analysis. Each 
short peptide string was submitted to the NetMHC 3.2 HLA-
binding algorithm. The results of this analysis were nanomolar 
(nM) binding affinity prediction scores for human HLA-A alleles 
and HLA-B alleles as indicated in the methods section.
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Figure 2. Tight binding mutated peptides derived from facilitating mutations and human hLa alleles. (A) allelic distribution of predicted tight-
binding peptides derived from facilitating mutations (mutated peptide affinity score < 50 nM aND wild-type peptide affinity score > 500 nM) from 
the cancer Gene census among hLa alleles (n = 52), null data not shown for n = 5 hLa alleles. (B) plot of tight-binding mutated peptides and peptides 
derived from faciliating mutations for each cognate hLa allele. Linear regression, y = 13.22(×) − 82.942, R2 as indicated.1284  OncoImmunology  Volume 1 Issue 8
Table 1. Facilitating, mutated strong binding hLa-a 02:01 peptides
FASTA wt wt Peptide nM (wt) FASTA mt mt Peptide nM (mt) Delta nM
> aLK-R401Q-wildtype-sequence-
1-hLa-a0201
FRVaLeYI 15009
> aLK-R401Q-mutant-sequence-1-
hLa-a0201
FQVaLeYI 29 14980
> Bap1-h169Q-wildtype-sequence-
1-hLa-a0201
FhFVsYVpI 13143
> Bap1-h169Q-mutant-sequence-1-
hLa-a0201
FQFVsYVpI 21 13122
> BRaF-K475M-wildtype-sequence-
1-hLa-a0201
GKWhGDVaV 15489
> BRaF-K475M-mutant-sequence-1-
hLa-a0201
GMWhGDVaV 13 15476
> cDK6-p199L-wildtype-sequence-
1-hLa-a0201
TpVDLWsV 14601
> cDK6-p199L-mutant-sequence-1-
hLa-a0201
TLVDLWsV 12 14589
> cheK2-p536L-wildtype-
sequence-1-hLa-a0201
RpaVcaaV 20392
> cheK2-p536L-mutant-sequence-
1-hLa-a0201
RLaVcaaV 25 20367
> eGFR-h773L-wildtype-sequence-
8-hLa-a0201
VMasVDNph 22464
> eGFR-h773L-mutant-sequence-8-
hLa-a0201
VMasVDNpL 48 22416
> FaNcF-p185L-wildtype-sequence-
1-hLa-a0201
RpaRFLssL 22304
> FaNcF-p185L-mutant-sequence-1-
hLa-a0201
RLaRFLssL 38 22266
> GNas-D141V-wildtype-sequence-
8-hLa-a0201
sVMNVpDFD 20809
> GNas-D141V-mutant-sequence-8-
hLa-a0201
sVMNVpDFV 24 20785
> ITK-G372V-wildtype-sequence-7-
hLa-a0201
FVQeIGsG 19247
> ITK-G372V-mutant-sequence-7-
hLa-a0201
FVQeIGsV 48 19199
> JaK1-e966V-wildtype-sequence-
8-hLa-a0201
FLpsGsLKe 17955
> JaK1-e966V-mutant-sequence-8-
hLa-a0201
FLpsGsLKV 11 17944
> JaK2-K539L-wildtype-sequence-
8-hLa-a0201
hMNQMVFhK 18253
> JaK2-K539L-mutant-sequence-8-
hLa-a0201
hMNQMVFhL 35 18218
> KRas-Q61L-wildtype-sequence-
10-hLa-a0201
cLLDILDTaGQ 6354
> KRas-Q61L-mutant-sequence-10-
hLa-a0201
cLLDILDTaGL 26 6328
> NOTch1-R1634L-wildtype-
sequence-1-hLa-a0201
KRaaeGWaa 21734
> NOTch1-R1634L-mutant-
sequence-1-hLa-a0201
KLaaeGWaa 24 21710
> RB1-p515L-wildtype-sequence-1-
hLa-a0201
FpWILNVL 10736
> RB1-p515L-mutant-sequence-1-
hLa-a0201
FLWILNVL 13 10723
> Tp53-p47L-wildtype-sequence-8-
hLa-a0201
aMDDLMLsp 10776
> Tp53-p47L-mutant-sequence-8-
hLa-a0201
aMDDLMLsL 11 10765
Table of representative mutated peptides from the cancer Gene census predicted to be tight binders (affinity < 50 nM) to hLa-a02:01, for which cog-
nate wild-type peptides are predicted to be non-binders (affinity > 500 nM). n = 15.
may bind with high affinity range from 0–11,005; the quartiles 
are bound by 0, 131, 768, 2,692 and 11,005. Analysis of mutated 
peptide binding to a limited number of MHC Class I alleles from 
mouse, rhesus macaque and chimpanzees demonstrates that 
these species may also be capable of presenting this set of anti-
gens (Fig. 1B–D).
Analysis of the number of tight-binding mutated peptides for 
which the corresponding wild-type peptide has a nonbinding 
score (greater than 500 nM) is reported in Figure 2. These pep-
tide-MHC pairs numbered 7,982 (8% of the total tight-binding 
mutated peptides). The mutations leading to peptides that may 
exhibit greater binding to HLA than wild-type counterparts are 
referred to as facilitating mutations. A partial set of facilitating 
mutations for HLA-A02:01 is collected in Table 1 (n = 15).
Neither the number of peptides binding each HLA molecule, 
nor facilitating mutations are equally distributed among the HLA 
alleles analyzed. However, the number of facilitating mutations 
each missense mutation, compared with the wild-type sequence. 
This table is organized with a FASTA-formatted identifier for each 
mutation and HLA pair, reference to the position of the mutation 
in the peptide string, the peptide length, and whether the peptide 
referenced is the wild-type or mutant sequence. Following the 
FASTA-formatted identifier is the peptide sequence and the nM 
binding affinity score for the peptide and indicated HLA allele. 
This order is repeated for the mutated peptide sequence and each 
row ends with the calculated difference in nM affinity between 
the wildtype and mutated peptides for an individual HLA allele 
(Table S2).
Some human HLA alleles present a broader repertoire of 
mutated peptides than others (Fig. 1A). The frequently studied 
human allele HLA-A0201 ranks 15th among 57 alleles in the 
breadth of its repertoire. The mean number of mutated peptides 
that human alleles may bind is 1,767 with a standard deviation 
of 2,377. The number of mutated peptides that any human allele www.landesbioscience.com OncoImmunology  1285
properties, we have identified peptides that we predict will dem-
onstrate enrich surface presentation as a result of enhanced HLA-
binding affinity.21
Mutated peptides are a class of antigens with superior prop-
erties as immunological targets for cancer therapy. Self-protein 
derived peptides must overcome multiple and redundant 
mechanisms of T-cell suppression due to peripheral tolerance.22 
Additionally, the frequency of autoreactive T cells is attenu-
ated due to central tolerance. Mutated peptides are absent in 
the thymus during development and are not endogenously 
expressed in normal tissues. Moreover, altered protein folding 
of mutated proteins generally reduces their stability. Reduced 
stability in some cases is observed in the presence of stabilizing 
the heat-shock 90 KDa protein (HSP90) and in other cases by 
the increased proteosomal degradation accounted for by pep-
tide and protein decay experiments.23 Loss-of-function of tumor 
suppressor genes can be facilitated by a rapid protein turn-
over due to destabilization. The increased source of peptides 
resulting from decreased stability can enrich these peptides as 
potential HLA binders as compared with their wild-type coun-
terparts, as in the case of neutral effects on HLA-binding affin-
ity.24 A simplistic mass action mechanism for increased peptide 
presentation may underlie the enhanced surface presentation of 
these antigens.
However, if the HLA-binding affinity of a peptide is increased 
due to a mutation, this may translate into increased presentation 
was highly associated with the total number of tight binding 
mutated peptides analyzed R = 0.97 (n = 57) (Fig. 2). There is no 
enrichment or depletion of facilitating mutations among peptid-
HLA pairs as represented in the Cancer Gene Census database, 
a collection of the observable functional missense mutations in 
human cancer (Fig. 3). The identified facilitating mutations are 
largely composed of peptides in which the mutated residue is 
located in a peripheral residue position (Fig. 4A and B).
In the large majority of peptide-MHC pairs that remain in 
the total data set, mutations exert limited effect upon the HLA-
binding scores. In this set of 79,733 neutral mutations, 79% of the 
tight-binding peptides retain < 50 nM binding scores with and 
without the point mutation numbers (Fig. 3). A partial set of neu-
tral mutations for HLA-A02:01 is collected in Table 2 (n = 15).
Discussion
In this work, we have analyzed peptides that contain mutated 
amino acids from 5685 mutations in 312 genes for binding to 
HLA alleles in silico. All genes and mutations were selected from 
the Cancer Gene Census and annotated in the COSMIC data-
base to have known functional roles in cancer.20 This curated data 
set of functional mutations was selected for analysis to facilitate 
vaccine efforts that may be able to exert immunological pressure 
on genes required for tumor cell survival. In addition to focus-
ing our search on genes and mutations with important survival 
Figure 3. Facilitating mutation distribution for human hLa-a and hLa-B alleles. plot of tight binding mutated peptides (< 50 nM mutated peptide 
affinity score) from the cancer Gene census and corresponding wild-type peptides affinity score for each cognate hLa allele. Light green background 
indicates the threshold (500 nM) of predicted non-binding wild-type peptides.1286  OncoImmunology  Volume 1 Issue 8
Figure 4. For figure legend, see page 1287.www.landesbioscience.com OncoImmunology  1287
Table 2. Neutral, mutated strong binding hLa-a 02:01 peptides
FASTA wt wt Peptide nM (wt) FASTA mt mt Peptide nM (mt) Delta nM
> aLK-R1275Q-wildtype-
sequence-3-hLa-a0201
GMaRDIYRa 43
> aLK-R1275Q-mutant-sequence-
3-hLa-a0201
GMaQDIYRa 33 10
> Bap1-h169Q-wildtype-
sequence-6-hLa-a0201
RTMeaFhFV 9
> Bap1-h169Q-mutant-sequence-
6-hLa-a0201
RTMeaFQFV 15 6
> BRaF-L618W-wildtype-
sequence-2-hLa-a0201
sILWMapeV 20
> BRaF-L618W-mutant-sequence-
2-hLa-a0201
sIWWMapeV 10 10
> cDK6-p199L-wildtype-
sequence-9-hLa-a0201
VLLQssYaTpV 12
> cDK6-p199L-mutant-sequence-
9-hLa-a0201
VLLQssYaTLV 13 1
> cRLF2-F232c-wildtype-
sequence-4-hLa-a0201
KLsKFILI 25
> cRLF2-F232c-mutant-sequence-
4-hLa-a0201
KLsKcILI 24 1
> eGFR-D761G-wildtype-
sequence-2-hLa-a0201
ILDeaYVMasV 11
> eGFR-D761G-mutant-sequence-
2-hLa-a0201
ILGeaYVMasV 20 9
> FBXW7-I563T-wildtype-
sequence-5-hLa-a0201
sLDTsIRV 23
> FBXW7-I563T-mutant-sequence-
5-hLa-a0201
sLDTsTRV 44 21
> GNa11-V223M-wildtype-
sequence-1-hLa-a0201
NVTsIMFLV 48
> GNa11-V223M-mutant-
sequence-1-hLa-a0201
NMTsIMFLV 9 39
> IDh2-V294M-wildtype-
sequence-5-hLa-a0201
LIDDMVaQV 18
> IDh2-V294M-mutant-sequence-
5-hLa-a0201
LIDDMMaQV 23 5
> JaK1-D660h-wildtype-
sequence-8-hLa-a0201
YLYGVcVRDV 23
> JaK1-D660h-mutant-sequence-
8-hLa-a0201
YLYGVcVRhV 15 8
> JaK2-K607N-wildtype-
sequence-4-hLa-a0201
KLshKhLV 44
> JaK2-K607N-mutant-sequence-
4-hLa-a0201
KLshNhLV 29 15
> KRas-Q22K-wildtype-
sequence-0-hLa-a0201
QLIQNhFV 42
> KRas-Q22K-mutant-sequence-
0-hLa-a0201
KLIQNhFV 11 31
> NOTch1-s1598I-wildtype-
sequence-5-hLa-a0201
FLReLsRV 40
> NOTch1-s1598I-mutant-
sequence-5-hLa-a0201
FLReLIRV 20 20
> ReT-D925h-wildtype-
sequence-3-hLa-a0201
sLFDhIYTT 13
> ReT-D925h-mutant-sequence-
3-hLa-a0201
sLFhhIYTT 32 19
> TcL1a-K23N-wildtype-
sequence-6-hLa-a0201
RLWaWeKFV 11
> TcL1a-K23N-mutant-sequence-
6-hLa-a0201
RLWaWeNFV 8 3
Table of representative mutated peptides from the cancer Gene census predicted to be tight binders (affinity < 50 nM) to hLa-a02:01, for which cog-
nate wild-type peptides are also predicted to be tight binders (affinity < 50 nM). n = 15.
of the mutant peptide. During the loading of peptides on HLA 
in the ER and endosomes, competition can occur. Thus, facili-
tating mutations are subject to this advantage in loading and pre-
sentation.24 Once exposed on the cell surface, stable HLA/B2M/
peptide complexes are presented for a relatively long time and 
hence have a higher chance to activate T cells.21,24 Interestingly, 
in a study that determined the antigen specificity of T cells in 
an immunosurveillance model of murine sarcoma, the mutated 
peptide from spectrin β2 was shown to contain a facilitating 
mutation. Identified in silico as a MHC Class I (H-2-Db) binder 
after exome sequencing, the VAVVNQIAL peptide possesses a 
binding score of 9 nM based on the methods used in this study. 
The cognate wildtype peptide VAVVNQIAR achieves only a 
score of 5304 nM.7 In part, the principle of HLA-specific pep-
tide anchor residues motivates the search for these target pep-
tides. However, the artificial neural network-trained binding 
approach of NetMHC 3.2 functions independently of the recog-
nized dominant influence that some residues acquire in periph-
eral positions. Therefore it was not surprising to observe the high 
prevalence of peptides with mutations in the anchor position 
within the population of facilitating mutations. This result indi-
cates that the machine-learning model embedded in NetMHC 
Figure 4 (See opposite page). Facilitating mutations utilize peripheral anchor residues. plot of tight binding mutated 8, 9, 10 and 11 mer peptides 
(mutated peptide affinity score < 50 nM) and corresponding wild-type peptides affinity score for each cognate hLa-a (a) and hLa-B (B) allele. Light 
green background indicates the threshold (500 nM) of predicted non-binding wild-type peptides. coloring indicates the position of each mutation in 
the peptide string (starting from the c terminus): dark blue (1), light blue (2), orange (3), light orange (4), dark green (5), light green (6), red (7), pink (8), 
purple (9), light purple (10), brown (11).1288  OncoImmunology  Volume 1 Issue 8
were used to generate a library of 8, 9, 10 and 11 amino acid long 
peptides for further in silico screening. Reference sequences for 
each gene were similarly acquired from the COSMIC database, 
and 8, 9, 10, and 11 amino acid wild-type peptides corresponding 
to each mutated peptide were also generated.
In silico prediction of antigen presentation. Peptides were 
submitted to NetMHC 3.2 for prediction of binding affin-
ity for all MHC Class I alleles available.18,30 Human HLA-A 
alleles: 01:01, 02:01, 02:02, 02:03, 02:06, 02:11, 02:12, 02:16, 
02:19, 02:50, 03:01, 11:01, 23:01, 24:02, 24:03, 25:01, 26:01, 
26:02, 26:03, 29:02, 30:01, 30:02, 31:01, 32:01, 33:01, 68:01, 
68:02, 69:01, 80:01; HLA-B alleles; 07:02, 08:01, 08:02, 08:03, 
15:01, 15:02, 15:03, 15:09, 15:17, 18:01, 27:03, 27:05, 35:01, 
38:01, 39:01, 40:01, 40:02, 44:02, 44:03, 45:01, 46:01, 48:01, 
51:01, 53:01, 54:01, 57:01, 58:01, and 73:01 were included 
in the analysis. Murine alleles: H-2-Db, H-2-Dd, H-2-Kb, 
H-2-Kd, H-2Kk, H-2Ld. Rhesus macaque alleles: Mamu-A01, 
Mamu-A02, Mamu-A11, Mamu-A2:201, Mamu-A26:01, 
Mamu-B01, Mamu-B03, Mamu-B08, Mamu-B17. Chimpanzees 
alleles: Patr-A01:01, Patr-A03:01, Patr-A04:01, Patr-A07:01, 
Patr-A09:01, Patr-B01:01, Patr-B24:01. Nanomolar affinity val-
ues for wild-type reference and mutation-derived peptides were 
ranked, with those less that 50 nM referred to “tight binders” and 
those less that 500 nM as “loose binders.” These thresholds were 
previously adopted by Istail et al.31
Data Analysis. Linear regression was analyzed with Graphpad 
Prism (GraphPad Software Inc.). Figures were generated with 
Graphpad Prism and Tableau Professional (Tableau Software).
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3.2 for predicting peptide-HLA binding confirms experimentally 
informed theoretical expectations.
This study provides an analysis of the Cancer Gene Census 
database revealing a subset of mutated peptides with superior 
HLA-binding affinity for the development of personalized pep-
tide vaccines that target functionally relevant targets in diverse 
cancer and diverse HLA haplotypes. For this approach, substan-
tial rationale exists for the continued use of immunostimula-
tory treatments such as anti-CTLA4 or anti-PD-1 monoclonal 
antibodies in combination with peptide vaccines.22 Still, in the 
clinical and experimental use of self peptides as tumor antigens, 
autoimmune responses are a source of significant toxicity when 
combined with anti-CTLA4 therapy.22,25 For this reason, as we 
and others previously stated, the discovery and characterization 
of tumor-specific epitopes is still a priority in immunotherapy. 
Exerting pressure on cancer cells with functional mutations that 
facilitate tumor survival may provide an additional level of pro-
tection, as the loss of such antigens may be detrimental to the 
tumorigenic phenotype. The generation of this evolutionary 
double bind is predicted to have superior effects in a mutating 
target cell population.26 This class of peptides displays conserved 
molecular homology and exerts lethal pressure on cells in relation 
to oncogenic properties, which underlies their theoretical value 
as clinical targets for T-cell therapy and as ligands for TCR-like 
antibodies.27–29 The results of this study are critical to the high-
throughput experimental validation of mutated tumor epitopes 
in anticipation of the broad implementation of personalized 
mutation-specific cancer vaccines.
Materials and Methods
Mutated peptide library generation. Point substitutions observed 
in cancer cell lines and tumor specimens were collected from the 
Catalogue of Somatic Mutations in Cancer (COSMIC) database 
in February 2011 and February 2012.20 Mutant genes were taken 
from the Cancer Genes of the Cancer Gene Census. This expand-
ing collection of validated cancer mutations is curated to maintain 
a collection of mutations extending functional properties to can-
cer cells.20 Gene mutations resulting in altered peptide sequences 
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